CDK1 Cancer Research Results

CDK1, Cyclin-dependent kinase 1: Click to Expand ⟱
Source:
Type:
CDK1, (Cyclin-dependent kinase 1) same as p34 (cdc2) kinase activity
Mitotic Gatekeeper, Essential Cell-Cycle Engine, and Therapeutic Vulnerability
Cell cycle control to gene expression regulation and apoptosis, CDK1 is intimately involved in many cellular events that are vital for cell survival.
CDK1 is a significant biomarker in various cancers, with its overexpression often correlating with aggressive tumor characteristics and poor prognosis. Targeting CDK1 may offer therapeutic potential, especially in cancers where its expression is linked to unfavorable outcomes.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
177- Api,    Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression
- in-vitro, BC, MDA-MB-231
Cyc↓, CycB/CCNB1↓, CDK1↓, P21↑, PCNA↝, HDAC↓, TumCP↓, TumCCA↑, ac‑H3↑, TumW↓, TumVol↓,
5639- BCA,    Biochanin A Induces Apoptosis in MCF-7 Breast Cancer Cells through Mitochondrial Pathway and Pi3K/AKT Inhibition
- in-vitro, BC, NA
TumCP↓, ROS↑, Apoptosis↑, Bcl-2↓, p‑PI3K↓, p‑Akt↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑, CycD3↓, CycB/CCNB1↓, CDK1↓, CDK2↓, CDK4↓, P21↑, p27/CDKN1B↑, P53↑, tumCV↓, PI3K↓, Akt↓,
417- CUR,    Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
- vitro+vivo, BC, MCF7 - vitro+vivo, BC, MDA-MB-231 - vitro+vivo, BC, MDA-MB-468
EZH2↓, DLC1↑, cycA1/CCNA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
4929- PEITC,  PacT,    Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
ChemoSen↑, Apoptosis↑, TumCCA↑, eff↑, CDK1↓, Bcl-2↓, BAX↑, cl‑PARP↑, SAL↑,
54- QC,    Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
- in-vitro, BC, MCF7
EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓, H3K27ac↓, TumCCA↑, CSCs↓, CDK1↓, CycB/CCNB1↓, Bcl-xL↓, Bcl-2↓, Nanog↓, H3↓,
913- QC,    Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression
- in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-435
TumCP↓, TumCCA↑, DNAdam↑, Chk2↑, CycB/CCNB1↓, CDK1↓, tumCV↓, p‑RB1↓, P21↑,
5036- SAS,    Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
xCT/SLC7A11↓, GSH↓, OS↑, Myc↓, CDK1↓, CD44↓, eff↑, TumCG↓,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 1,   hyperG↓, 1,   ROS↑, 2,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

KLF5↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt↑, 2,   p‑Akt↓, 2,   Apoptosis↑, 2,   ASK1↑, 1,   BAX↑, 2,   Bcl-2↓, 4,   Bcl-xL↓, 1,   BIM↑, 1,   Casp3↑, 2,   Casp9↑, 2,   Chk2↑, 1,   Cyt‑c↑, 1,   Myc↓, 1,   p27/CDKN1B↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 2,   H3↓, 1,   ac‑H3↑, 1,   tumCV↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,   PCNA↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 8,   CDK2↓, 1,   CDK4↓, 1,   CDK4↑, 2,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 4,   CycD3↓, 1,   P21↑, 3,   p‑RB1↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   CSCs↓, 1,   EMT↓, 1,   p‑GSK‐3β↑, 1,   H3K27ac↓, 1,   HDAC↓, 1,   mTOR↑, 2,   Nanog↓, 2,   NOTCH1↓, 1,   OCT4↓, 1,   PI3K↓, 1,   PI3K↑, 2,   p‑PI3K↓, 1,   SAL↑, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

DLC1↑, 2,   E-cadherin↑, 1,   KLF2↓, 1,   MMP2↓, 1,   PKA↓, 1,   TumCP↓, 3,   Vim↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 5,   eff∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BG↓, 1,   EZH2↓, 2,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,   TumVol↓, 2,   TumW↓, 1,  
Total Targets: 73

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CDK1, Cyclin-dependent kinase 1
2 Quercetin
1 Apigenin (mainly Parsley)
1 Biochanin A
1 Curcumin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Phenethyl isothiocyanate
1 Paclitaxel/Taxol
1 Sulfasalazine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:382  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page